相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pertuzumab in gastrointestinal cancer
Do-Youn Oh et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell CarcinomaA Trial of the ECOG-ACRIN Cancer Research Group (E2804)
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
Andres M. Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
Ismael Riquelme et al.
ONCOTARGET (2015)
PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
Xianglan Zhang et al.
ONCOLOGY (2015)
Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors
Alexandre Andrade Anjos Jacome et al.
GASTRIC CANCER (2014)
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Yoon-Koo Kang et al.
INVESTIGATIONAL NEW DRUGS (2014)
被撤回的出版物: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer
Corey J. Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Correction: mtDNA T8993G Mutation-Induced F1F0-ATP Synthase Defect Augments Mitochondrial Dysfunction Associated with hypoxia/reoxygenation: The Protective Role of Melatonin
Wen-Yi Huang et al.
PLoS One (2014)
Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
Temitope Sasore et al.
PLOS ONE (2014)
Characteristics of gastric cancer in Asia
Rubayat Rahman et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial
Shingo Takano et al.
ONCOTARGETS AND THERAPY (2014)
HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
Marisa Mariani et al.
ONCOTARGET (2014)
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
Sara A. Hurvitz et al.
SPRINGERPLUS (2014)
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
T. Brodowicz et al.
ANNALS OF ONCOLOGY (2013)
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
N. C. Tebbutt et al.
BRITISH JOURNAL OF CANCER (2013)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Beata Holkova et al.
CLINICAL CANCER RESEARCH (2013)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
Matrix Metalloproteinase-14 Is a Negative Prognostic Marker for Patients with Gastric Cancer
Liang He et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
C. Gomez-Martin et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
K. -W. Lee et al.
INVESTIGATIONAL NEW DRUGS (2013)
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Gastric cancer epidemiology and risk factors
Douglas E. Guggenheim et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer SWOG S0536
Edward S. Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Tom Waddell et al.
LANCET ONCOLOGY (2013)
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Florian Lordick et al.
LANCET ONCOLOGY (2013)
Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer
Tao Wu et al.
MEDICAL ONCOLOGY (2013)
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study
Kazunari Tateishi et al.
MEDICAL ONCOLOGY (2013)
Correction: Internalization of Met Requires the Co-Receptor CD44v6 and Its Link to ERM Proteins
Susanne Hasenauer et al.
PLoS One (2013)
Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
Liang Huang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Matrix Metalloproteinase-9 as a Prognostic Factor in Gastric Cancer: A Meta-Analysis
Qiong-Wen Zhang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas
Isabela Martins Gonzaga et al.
BMC CANCER (2012)
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
J. H. Yi et al.
BRITISH JOURNAL OF CANCER (2012)
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
David J. Adelstein et al.
INVESTIGATIONAL NEW DRUGS (2012)
Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer
Yasushi Goto et al.
INVESTIGATIONAL NEW DRUGS (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Therapeutic strategies in epithelial ovarian cancer
Ayako Kim et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
Chin-Tung Chen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue
Robert Partyka et al.
MEDICAL SCIENCE MONITOR (2012)
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
Wen-Ping Wang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells
Radhakrishnan Ganesh et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima et al.
CLINICAL CANCER RESEARCH (2011)
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Chul Kim et al.
INVESTIGATIONAL NEW DRUGS (2011)
Preliminary Efficacy of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
Heribert Juergens et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
Federica Cuppone et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Yesid Alvarado et al.
TARGETED ONCOLOGY (2011)
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
Weijing Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
Fotios Loupakis et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C. Pinto et al.
BRITISH JOURNAL OF CANCER (2009)
Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
Guanzhen Yu et al.
CLINICAL CANCER RESEARCH (2009)
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
Federico Rojo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
GK Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
